Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.
Chronic HBV infects 350 million people causing cancer and liver failure. We aimed to assess the safety and efficacy of plasmid DNA (pSG2.HBs) vaccine, followed by recombinant modified vaccinia virus Ankara (MVA.HBs), encoding the surface antigen of HBV as therapy for chronic HBV. A secondary goal wa...
Main Authors: | James S Cavenaugh, Dorka Awi, Maimuna Mendy, Adrian V S Hill, Hilton Whittle, Samuel J McConkey |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-02-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3039644?pdf=render |
Similar Items
-
Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.
by: Cavenaugh, J, et al.
Published: (2011) -
Safety, immunogenicity, and efficacy results of a phase II trial of therapeutic vaccines for chronic HBV in the Gambia.
by: McConkey, S, et al.
Published: (2004) -
Novel oligonucleotide assay detects HBV pre-core and basal core mutations in HBV-infected Gambians
by: Mendy, M, et al.
Published: (2006) -
Therapeutic vaccination against hepatitis B virus using heterolgous prime boost strategy with DNA and modified vaccinia virus ankara vectors
by: McConkey, S, et al.
Published: (2003) -
Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis.
by: Gilbert, S, et al.
Published: (2006)